are examples of consortia, which are formed voluntarily by scientists from multiple sectors, that have no source of funding. Table 1 and the associated Supplementary Information provide an extensive list of consortia in drug de velopment and pharmacogenomics. For each consortium, the membership, funding source, and link to the relevant website are provided. Table 1 and the associated Supplementary Information provide a list of active con sortia focused on drug development, in cluding drug discovery. Four consortia focused on scientific issues that are rele vant to drug development, and in partic ular, drug-drug interactions are described in more detail below.
CONSORTIA FOCUSING ON DRUG DEVELOPMENT
The International Transporter Consor tium (ITC) was founded without financial support in 2007 by key scientists with ex pertise in drug metabolism, transport, and pharmacokinetics from multiple sectors (ac ademia, industry, and the US Food and Drug Administration (FDA)). ITC investigators from the United States, Europe, and Asia are interested in the role of drug transporters in drug safety and efficacy (https ://www.itc trans porter.org/). The first workshop held in 2008 was a collaborative effort with the FDA that resulted in a white paper on membrane transporters in drug development 1 that ex emplified the aims of the FDA's Critical Path Initiative (https ://www.fda.gov/scien cere sea rch/scien ceandresea rchspeci altopic s/ criti calpathiniti ative ). Since 2008, a total of three workshops and two joint workshops on drug transporters in absorption, distribu tion, metabolism, and elimination have pro vided critical updates and recommendations that were incorporated into several white papers, each addressing important areas in drug development, including drug-drug interactions (DDIs), transporter polymor phisms, emerging transporters of clinical importance, in vitro methods for transporter evaluation, recommendations related to clinical study design, and potential clinical probes and endogenous biomarkers, among others. 2, 3 Although great advances have been made in our understanding of factors affecting transporter function and clinical relevance, challenges remain, and the knowl edge gaps must continue to be addressed via collaborative efforts, such as the ITC. The To build a collaborative network among the growing number of university-led drug discovery centers and programs.
Academia, Industry Industry
Accelerating Therapeutics for Opportunities in Medicine (ATOM)
The mission is to transform drug discovery by accelerating methods and tools used in drug discovery and development.
Academia, Industry
Public-private partnership
Biomarker Consortium
To discover and validate endogenous substrates for transporters involved in drug absorption and elimination.
Academia, Industry Industry
Drug-Induced Liver Injury Network (DILIN)
To collect and analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements.
Academia NIH

Kinetics for Drug Discovery (K4DD) Consortium
To enable the adoption of drug-target binding kinetics analysis in the drug discovery decision-making process, and thereby contribute to the development of a new generation of improved medicinal products. Understanding and optimizing osteosarcoma treatment through genetics.
Academia Public
Metformin Genetics (MetGen Plus)
Diabetes studies that have genetic data and metformin and other antidiabetes drug treatment outcome measures.
Academia None
Pharmacogenomics in Childhood Asthma (PICA)
Bring together asthma studies that have genetic data and treatment outcome measures.
Academia None
Prediction ADR Consortium (Prediction-ADR) Discover the genetic factors predisposing patients to adverse drug reactions (ADRs) from cardiovascular disease (CVD) drugs.
Academia European Community
The International Serious Adverse Events Consortium (ISAEC)
To identify DNA-variants useful in understanding the risk of drug-related serious adverse events (SAEs).
Academia, Industry, Government
Non profit
The Pharmacogenomics of Clozapine-Induced Myocarditis (PROCLAIM) Consortium
To uncover genomic markers that could be used preemptively by clinicians to identify those patients at highest risk for myocarditis from clozapine therapy and identify the mechanism by which clozapine induces myocardial inflammation and damage.
Academia Public
The hyperlink and references published by the consortia are listed in Supplementary Information. IVIVE, in vitro to in vivo extrapolation; NIH, National Institutes of Health; SMEs, small and medium-sized enterprises; US NAM, US National Academy of Medicine. PERSPECTIVES concentrations) mediated by transporters to predict drug disposition and tissue concentra tions, verified through imaging modalities. 7 See Supplementary Information for a list of publications from UWRAPT. The Biomarker Consortium was founded recently in Japan by Drs Hiroyuki Kusuhara and Yuichi Sugiyama through support from industry. Many challenges remain in the prediction of transportermediated DDIs. These include induction and inhibition of transporters, as well as the effects of genetic polymorphisms in modulating DDIs. The goals of this consortium are to advance the characterization of endogenous substrates to provide compelling evidence that endog enous compounds are surrogate probes to quantitatively predict transportermediated DDIs and to establish physiologicallybased pharmacokinetic models for predicting the effects of investigational compounds on en dogenous compounds. To achieve these goals, this project will provide evidence at three lev els: (i) in vitro data, (ii) animal data, and (iii) clinical data to increase the robustness of the physiologicallybased pharmacokinetic mod els. Finally, the project will disclose the data to support the rationale for use of the endog enous probes in a publicly accessible database and in published manuscripts. Our most recent finding using coproporphyrin I as an endogenous biomarker will serve as a model for this consortium 8 (Figure S1) .
The Innovation & Quality (IQ) Consor tium is a dynamic and technically focused organization that impacts many areas of pharmaceutical development and regula tion. Membership is only opened to phar maceutical industry. IQ supports many leadership groups and working groups fo cusing on issues in pharmaceutical science including the Translational and ADME Sciences Leadership Group, which focuses on studies related to drug absorption, distribution, metabolism, and elimination, the Clinical Pharmacology Leadership Group, and others (https ://iqcon sorti um.org/about/ ).
Other consortia and networks relevant to drug discovery and development that are funded by NIH or public-private fundings include the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consor tium, DrugInduced Liver Injury Network (DILIN), Kinetics for Drug Discovery (K4DD) consortium, Illuminating the Druggable Genome (IDG), and Structural Genomics Consortium (SGC) (see Table 1 , Supplementary Information).
CONSORTIA FOCUSING ON PHARMACOGENOMICS
Pharmacogenomics research is focused on understanding how an individual's genes affect his or her response to medicines. Many of the networks or consortia that Figure 1 Illustration of multidisciplinary consortia that support precompetitive drug development and pharmacogenomics research.
focus on pharmacogenomics research are founded in the United States or Europe but include researchers around the world (Table 1, Figure 1 , and Supplementary Information). Furthermore, many phar macogenomics consortia study multi ple ethnic groups and diseaserelated populations. Below, we describe the Pharmacogenomics Research Network (PGRN) as an example of a broadbased pharmacogenomics research consortium, followed by a brief description of dis easespecific or drugspecific pharmacog enomics research consortia.
The PGRN is an NIHfunded program whose mission is to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects. From 2000 to 2015, a total of 16 pharmacogenom ics research groups, 7 network resources, and a Pharmacogenomics Knowledge Base have been supported by various NIH Institutes, led by the National Institute of General Medical Sciences. Since 2015, the PGRN has included three specialized centers (P50 grants) and six resources (R24 grants) (https ://www.pgrn.org/resea rchpages.html). 9 In 2015, the PGRN membership structure was opened, and there are currently over 600 members globally who are active in pharma cogenomics research, teaching, and clinical work. Members avail themselves of activities and resources coordinated by the PGRN Hub, including annual scientific meetings, a website rich in pharmacogenomics research tools and news (www.pgrn.org), social media posts, monthly Research in Progress Seminars, and quarterly memberwide calls. The major scientific accomplishments of PGRNfunded researchers include discov ery of genetic polymorphisms in genes that are critical for disposition of and response to many drugs, including those used to treat cancer and cardiovascular, respiratory, neu ropsychiatric, and rheumatologic diseases. Additional accomplishments include appli cation of genomewide association methods to pharmacogenomics (https ://www.pgrn. org/rikenpubli catio ns.html), functional genomics studies of common and rare vari ants, development and utilization of induced pluripotent stem cells, and clinical imple mentation and standardization of pharma cogenomics testing (see Data S1, reading lists to learn more about PGRN).
Future directions
Financial support from NIH for the PGRN will end on June 30, 2020. PGRN is actively exploring various partnerships and mechanisms within the United States and globally to foster its continued leader ship role in pharmacogenomics research.
In addition to the PGRN, there are at least 20 pharmacogenomics consortia where re searchers from around the world share data and knowledge to answer questions in phar macogenomics. These consortia may focus on particular drug classes, diseases, or ad verse drug events ( Table 1 , Supplementary Information). Drugspecific pharmacog enomics consortia are formed (see https ://www.pgrn.org) to pool and expand samples for increased power in pharma cogenomics research and to bring scientists and clinicians together to participate in study design, sample collection, and data analysis and interpretation. An example of a drugspecific consortium is MetGen Plus (formerly MetGen, see https ://www. pgrn.org/metgen.html). This consortium originally began with a focus on identify ing pharmacogenomic factors that associate with response to metformin, which is first line therapy for type 2 diabetes. Motivated by common interest, the original goal of the consortium was to replicate phenotypic and genetic findings relating to metformin re sponse through collaboration. 10 This goal expanded to include other antidiabetic drugs. Examples of diseasefocused and adverse drug reactionfocused pharmacogenomics research consortia are the African American Cardiovascular Pharmacogenomics Consortium (ACCOUNT), Genetics of Osteosarcoma (GOConsortium), The Inter national Serious Adverse Events Consortium (ISAEC), and the Prediction ADR Consortium (PredictionADR). In ad dition, there are many other consortia, which were established previously, but have sunset ted due to completion of the project or lack of funding (e.g., see https ://www.pgrn.org/ rikenproje cts.html).
CONCLUSIONS
Diverse consortia exemplified in this per spective have greatly enhanced precompet itive research in drug development sciences and pharmacogenomics. Diseasespecific scientific consortia have facilitated and empowered large genomewide association studies of human disease. Increasingly, drugspecific pharmacogenomics con sortia are enabling genomewide stud ies of pharmacogenomics phenotypes ( Table 1) . It is envisioned that such con sortia will increase in number as only a fraction of approved drugs have been stud ied using genomewide approaches. Similarly, multisector consortia such as the ITC, the Biomarker Consortium, and UWRAPT have enabled precompetitive research by providing muchneeded ex pertise and knowledge that informs drug development. Though some consortia end naturally when their purpose is fulfilled, sustaining consortia is frequently challeng ing, often because of funding issues. Most consortia are formed by motivated scien tists, often from academia, with industry partners. A byproduct of many of these consortia is that they support global col laborations and scientific exchange in drug development and pharmacogenomics. In the future, consortia focused on pharma cogenomics, biomarkers, special popu lations, and modeling and simulation of new drugs and therapies, as well as many older drugs, will be formed to advance pre cision medicine. Clinical pharmacologists should continue to support these scientific consortia through membership, funding, and active participation.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical Pharmacology & Therapeutics website (www.cpt-journal.com). Figure S1 . The newly established biomarker consortium to discovery and validate endogenous substrates for transporters involved in drug absorption and elimination. Three main approaches are illustrated in this figure.
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